AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

MYX Mayne Pharma Group Limited

Healthcare · Medical Distribution · website · 491 employees
$2.93
52wk 2.04 – 6.50
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$238.05M
P/E (trailing)
P/E (forward)
-12.74
EPS (trailing)
-1.04
Dividend yield
Payout ratio
0.0%
Beta
1.00
EV / EBITDA
7.14
Price / Book
0.67
ROE
-20.6%
Operating margin
-10.2%
Net margin
-20.4%
Total cash
$67.45M
Total debt
$42.47M
Current ratio
1.32
Debt / Equity
0.12
Free cash flow
$-15.25M
Avg volume
235,618
Latest annual results (FY ending 30 Jun 2024)
  • Revenue$387.90M
  • Gross profit$218.28M
  • Operating income-$139.31M
  • Net income-$174.23M
  • Diluted EPS-2.12
  • Free cash flow-$36.16M
  • Net debt-$71.25M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9